| Literature DB >> 35711367 |
Zunmin Wan1, Xiaohong Li2, Jinghua Sun1,3, Xiaohua Li2, Zhongzhen Liu3, Haojian Dong2, Qing Zhou3, Hailong Qiu2, Jinjin Xu3, Tingyu Yang1,3, Wen-Jing Wang3, Yanqiu Ou2.
Abstract
The lack of accessible noninvasive tools to examine the molecular alterations limits our understanding of the causes of total anomalous pulmonary venous connection (TAPVC), as well as the identification of effective operational strategies. Here, we consecutively enrolled peripheral leukocyte transcripts of 26 preoperative obstructive and 22 non-obstructive patients with TAPVC. Two-hundred and fifty six differentially expressed mRNA and 27 differentially expressed long noncoding RNA transcripts were dysregulated. The up-regulated mRNA was enriched in the hydrogen peroxide catabolic process, response to mechanical stimulus, neutrophil degranulation, hemostasis, response to bacterium, and the NABA CORE MATRISOME pathway, all of which are associated with the development of fibrosis. Furthermore, we constructed predictive models using multiple machine-learning algorithms and tested the performance in the validation set. The mRNA NR3C2 and lncRNA MEG3 were screened based on multiple iterations. The random forest prediction model can predict preoperative obstruction patients in the validation set with high accuracy (area under curve = 1; sensitivity = 1). These data highlight the potential of peripheral leukocyte transcripts to evaluate obstructive-related pathophysiological alterations, leading to precision healthcare solutions that could improve patient survival after surgery. It also provides a novel direction for the study of preoperative obstructive TAPVC.Entities:
Keywords: MEG3; machine learning; peripheral leukocyte transcripts; preoperative obstruction; total anomalous pulmonary venous connection
Year: 2022 PMID: 35711367 PMCID: PMC9194086 DOI: 10.3389/fcvm.2022.892000
Source DB: PubMed Journal: Front Cardiovasc Med ISSN: 2297-055X
Clinical characteristics of preoperative obstructive patients and non-obstructive patients.
|
|
| ||
|---|---|---|---|
| Surgical age, d, median (Q1, Q3) | 7.5 (3.0, 17.3) | 120.0 (60.0, 1186.3) | <0.001 |
| Male, | 16 (61.5) | 12 (54.5) | 0.62 |
| Surgical weight, kg, median (Q1, Q3) | 3.15 (2.90, 3.40) | 5.25 (4.45, 12.63) | <0.001 |
| Prematurity, | 2 (7.7) | 2 (9.1) | 1.00 |
| Associated cardiac lesion, | |||
| Patent ductus arteriosus | 16 (61.5) | 6 (27.3) | 0.02 |
| Atrial septal defect | 26 (100) | 22 (100) | 1.00 |
| Tricuspid insufficiency | 8 (30.8) | 17 (77.3) | 0.00 |
| Ventricular septal defect | 1 (3.8) | 0.00 | 1.00 |
| Pulmonary artery stenosis | 1 (3.8) | 2 (9.1) | 0.59 |
| Coarctation of aorta | 1 (3.8) | 0.00 | 1.00 |
| Mitrial insufficiency | 3 (11.5) | 2 (9.1) | 1.00 |
| Coronary artery pulmonary vein fistula | 1 (3.8) | 0.00 | 1.00 |
| Pulmonary hypertenson | 17 (51.5) | 16 (48.5) | 0.85 |
| Anatomic type, n (%) | 0.13 | ||
| Supracardiac | 15 (57.7) | 10 (45.5) | |
| Cardiac | 4 (15.4) | 9 (40.9) | |
| Infracardiac | 6 (23.0) | 1 (4.5) | |
| Mixed | 1 (3.8) | 2 (9.1) | |
| PVO in CT/Echo examination/ oxygen saturation, n (%) | 7 (26.9) | 0.00 | 0.01 |
| Preoperative poor status (intubation, heart failure, breath failure), n (%) | 3 (11.5) | 5 (22.7) | 0.30 |
| Emergency operation, n (%) | 5 (19.2) | 3 (13.6) | 0.71 |
| Use of sutureless repair, n (%) | 18 (69.2) | 5 (22.7) | <0.001 |
| CPB time, min, median (Q1, Q3) | 115 (84, 158) | 102 (73, 122) | 0.10 |
| Aortic crossclamp time (min) | 58 (47, 87) | 54 (40, 67) | 0.27 |
| Postoperative conditions | |||
| Duration of ventilation, h, median (Q1, Q3) | 99 (52, 146) | 52 (16, 124) | 0.03 |
| CCU stay, h, median (Q1, Q3) | 4 (2, 5) | 2 (2, 5) | 0.28 |
| Post-operative PVO, | 2 (7.7) | 1 (4.5) | 0.18 |
| Mortality, | 2 (7.7) | 1 (4.5) | 1.00 |
Figure 1Enrichment results of obstructive TAPVC transcripts. (A) PCA map for all genes; (B) volcano map display of mRNA and lncRNA DEGs. Red indicates up-regulated genes; yellow indicates down-regulated genes; and blue indicates genes without significant changes; (C) GO terms for up-regulated mRNA; (D) percentage of CD8 T-cells; (E) heatmap of differentially expressed mRNA; (F) heatmap of differentially expressed lncRNA.
Figure 2Model feature. (A) Top five features in order of importance; (B) overlap between NR3C2, MEG3, and mRNA, lncRNA DEGs; (C,D) the expression between the obstructive and non-obstructive TAPVC patients of NR3C2 in the training set and the validation set, respectively, Wilcoxon-Mann-Whitney; (C) NR3C2; (D) MEG3; (E) qRT-PCR result for NRC32; (F) qRT-PCR result for MEG3.
Figure 3Machine learning model of preoperative obstructive TAPVC. (A,B) ROC curve of the training set and validation set; green indicates the NR3C2 model; blue indicates the MEG3 model; red indicates the combined model. (A) training set; (B) validation set; (C) evaluation index of the model.